NO20074324L - Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorer - Google Patents

Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorer

Info

Publication number: NO20074324L
Authority: NO; Norway
Prior art keywords: alkyl; aryl; substituted; heteroaryl; hydrogen
Prior art date: 2005-01-25

Application number

NO20074324A

Other languages

English (en)

Norwegian (no)

Inventor

Dale S Dhanoa

Oren Becker

Silvia Noiman

Yael Marantz

Rosa E Melendez

Laurence Wu

Ashis K Saha

Mercedes Lobera

Anurag Sharadendu

Xiang Y Yu

Merav Fichman

Pini Orbach

Sharon Shacham

Srinivasa Rao Cheruku

Hanock Senderowitz

Original Assignee

Epix Delaware Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-25

Filing date

2007-08-24

Publication date

2007-10-25

2007-08-24 Application filed by Epix Delaware Inc filed Critical Epix Delaware Inc

2007-10-25 Publication of NO20074324L publication Critical patent/NO20074324L/no

Links

150000004982 aromatic amines Chemical class 0.000 title 1
239000000203 mixture Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 4
125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
208000008589 Obesity Diseases 0.000 abstract 2
125000002877 alkyl aryl group Chemical group 0.000 abstract 2
-1 arylamine compounds Chemical class 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
235000020824 obesity Nutrition 0.000 abstract 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
108091005435 5-HT6 receptors Proteins 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000005907 alkyl ester group Chemical group 0.000 abstract 1
150000003975 aryl alkyl amines Chemical class 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
208000010643 digestive system disease Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000004438 haloalkoxy group Chemical group 0.000 abstract 1
125000001188 haloalkyl group Chemical group 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000004962 physiological condition Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
239000002464 receptor antagonist Substances 0.000 abstract 1
229940044551 receptor antagonist Drugs 0.000 abstract 1
208000023504 respiratory system disease Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
229940076279 serotonin Drugs 0.000 abstract 1
150000003457 sulfones Chemical class 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Obesity (AREA)
Hematology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

NO20074324A 2005-01-25 2007-08-24 Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorer NO20074324L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US64695705P	2005-01-25	2005-01-25
US70185305P	2005-07-22	2005-07-22
PCT/US2006/002718 WO2006081332A1 (en)	2005-01-25	2006-01-25	Substituted arylamine compounds and their use as 5-ht6 modulators

Publications (1)

Publication Number	Publication Date
NO20074324L true NO20074324L (no)	2007-10-25

Family

ID=36406535

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20074324A NO20074324L (no)	2005-01-25	2007-08-24	Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorer

Country Status (14)

Country	Link
US (2)	US7968538B2 (pt)
EP (1)	EP1856075A1 (pt)
JP (2)	JP5186219B2 (pt)
KR (1)	KR20070097590A (pt)
AU (1)	AU2006209216A1 (pt)
BR (1)	BRPI0606110A2 (pt)
CA (1)	CA2595607C (pt)
IL (1)	IL184705A0 (pt)
MA (1)	MA29429B1 (pt)
MX (1)	MX2007008279A (pt)
NO (1)	NO20074324L (pt)
NZ (1)	NZ556761A (pt)
RU (1)	RU2440996C2 (pt)
WO (1)	WO2006081332A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7482337B2 (en) *	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7153858B2 (en)	2003-01-31	2006-12-26	Epix Delaware, Inc.	Arylpiperazinyl compounds
US20050222175A1 (en) *	2004-03-31	2005-10-06	Dhanoa Dale S	New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) *	2003-03-31	2009-11-03	Epix Delaware, Inc.	Piperidinylamino-thieno[2,3-D] pyrimidine compounds
DE102004009039A1 (de) *	2004-02-23	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7488736B2 (en) *	2004-05-17	2009-02-10	Epix Delaware, Inc.	Thienopyridinone compounds and methods of treatment
DE102004030502A1 (de) *	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
US7598265B2 (en) *	2004-09-30	2009-10-06	Epix Delaware, Inc.	Compositions and methods for treating CNS disorders
US7407966B2 (en) *	2004-10-07	2008-08-05	Epix Delaware, Inc.	Thienopyridinone compounds and methods of treatment
US7576211B2 (en) *	2004-09-30	2009-08-18	Epix Delaware, Inc.	Synthesis of thienopyridinone compounds and related intermediates
EP1676842A1 (en) *	2004-12-30	2006-07-05	Laboratorios Del Dr. Esteve, S.A.	Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
BRPI0606110A2 (pt)	2005-01-25	2009-06-02	Epix Delaware Inc	compostos de arilamina substituìdos e seu uso como 5 - ht6 moduladores
AR061637A1 (es) *	2006-06-26	2008-09-10	Epix Delaware Inc	Composiciones y metodos de tratamiento de trastornos del snc
EP2102157B1 (en)	2006-12-19	2011-06-22	F. Hoffmann-La Roche AG	Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
CA2681034A1 (en)	2007-03-23	2008-10-02	Abbott Gmbh & Co. Kg	Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
ES2353297B1 (es) *	2008-03-18	2011-09-26	Laboratorios Del Dr. Esteve, S. A.	Procedimiento para la preparación de n-(1-feniletil)anilinas, sales, y solvatos de las mismas útiles como antagonistas de 5-ht6 de serotonina.
EP2103596A1 (en)	2008-03-18	2009-09-23	Laboratorios Del. Dr. Esteve, S.A.	Process for the preparation of N-(phenylethyl) anilines salts and solvates thereof useful as serotonin 5-HT6 antagonists
WO2010065743A2 (en) *	2008-12-03	2010-06-10	Nanotherapeutics, Inc.	Bicyclic compounds and methods of making and using same
CA2789434A1 (en) *	2010-02-11	2011-08-18	Vanderbilt University	Benzisoxazoles and azabenzisoxazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
TWI458145B (zh)	2011-12-20	2014-10-21	Ind Tech Res Inst	超導材料的接合方法
KR102692169B1 (ko) *	2013-12-03	2024-08-05	인트라-셀룰라 써래피스, 인코퍼레이티드.	신규한 방법
WO2018071233A1 (en)	2016-10-12	2018-04-19	Intra-Cellular Therapies, Inc.	Amorphous solid dispersions
WO2018106667A1 (en) *	2016-12-05	2018-06-14	Microbiotix, Inc.	Broad-spectrum inhibitors of filoviruses
RU2767410C2 (ru)	2017-03-24	2022-03-17	Интра-Селлулар Терапиз, Инк.	Новые композиции и способы
KR102704242B1 (ko)	2017-06-20	2024-09-09	임브리아 파마슈티칼스, 인크.	심장 대사의 효율을 증가시키기 위한 조성물 및 방법
KR101992621B1 (ko)	2017-12-07	2019-09-27	주식회사 온코빅스	암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
WO2020047241A1 (en)	2018-08-29	2020-03-05	Intra-Cellular Therapies, Inc.	Novel compositions and methods
CN112584838A (zh)	2018-08-31	2021-03-30	细胞内治疗公司	新方法
CN112584837A (zh)	2018-08-31	2021-03-30	细胞内治疗公司	新方法
US12318382B2 (en)	2018-10-17	2025-06-03	Imbria Pharmaceuticals, Inc.	Methods of treating rheumatic diseases using trimetazidine-based compounds
WO2020243120A1 (en)	2019-05-31	2020-12-03	Imbria Pharmaceuticals, Inc.	Methods of treating fibrosis using compounds that promote glucose oxidation
JP7673040B2 (ja)	2019-07-07	2025-05-08	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規方法
KR20220053557A (ko)	2019-07-17	2022-04-29	2692372 온타리오 인크.	벤젠술폰아미드 유도체 및 그의 용도
CN112574201B (zh) *	2019-09-29	2024-04-19	四川科伦博泰生物医药股份有限公司	芳基胺类化合物、包含其的药物组合物及其制备方法和用途
US11530184B2 (en)	2020-06-30	2022-12-20	Imbria Pharmaceuticals, Inc.	Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en)	2020-06-30	2023-10-10	Imbria Pharmaceuticals, Inc.	Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US12029718B2 (en)	2021-11-09	2024-07-09	Cct Sciences, Llc	Process for production of essentially pure delta-9-tetrahydrocannabinol
CN116745264A (zh)	2020-11-20	2023-09-12	2692372安大略公司	用于kras修饰的方法和组合物
US11883396B2 (en)	2021-05-03	2024-01-30	Imbria Pharmaceuticals, Inc.	Methods of treating kidney conditions using modified forms of trimetazidine
US12414948B2 (en)	2022-05-18	2025-09-16	Intra-Cellular Therapies, Inc.	Methods

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1211359B (de) *	1955-11-29	1966-02-24	Oreal	Oxydationsmittelfreies Kaltfaerbemittel fuer menschliches Haar
JPH0413669A (ja)	1990-04-27	1992-01-17	Mitsui Toatsu Chem Inc	新規ピリミジンジオン誘導体及び該化合物を含有する抗不整脈剤
DE4238994A1 (de)	1992-11-19	1994-05-26	Basf Ag	Aniline als Markierungsmittel für Mineralöle
JPH07300474A (ja) *	1994-05-02	1995-11-14	Asahi Chem Ind Co Ltd	テトラハイドロキノキサリン誘導体およびその用途
FR2722788B1 (fr) *	1994-07-20	1996-10-04	Pf Medicament	Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
KR970705560A (ko)	1995-08-02	1997-10-09	호아껭 우리아치 토렐로	항진균 활성을 갖는 신규한 카르복사미드(new carboxamides with antifungal activity)
FR2740134B1 (fr) *	1995-10-18	1998-01-09	Pf Medicament	Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
US6391871B1 (en)	1996-09-20	2002-05-21	John W. Olney	Preventing neuronal degeneration in Alzheimer's disease
US20010051719A1 (en)	1996-12-19	2001-12-13	Smithkline Beecham P.L.C.	Novel compounds
EP0971713B1 (en)	1997-03-03	2003-05-28	Eisai Co., Ltd.	Use of cholinesterase inhibitors to treat disorders of attention
FR2761064B1 (fr) *	1997-03-20	1999-06-04	Pf Medicament	Piperazines derivees d'amines cycliques, leur preparation et leur application comme medicaments
WO1999021834A1 (en) *	1997-10-27	1999-05-06	Neurosearch A/S	Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
JP4135318B2 (ja) *	1997-12-15	2008-08-20	アステラス製薬株式会社	新規なピリミジン−５−カルボキサミド誘導体
IT1304904B1 (it)	1998-09-11	2001-04-05	Eisai Co Ltd	Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
ES2219302T3 (es)	1999-01-07	2004-12-01	Wyeth	Derivados de arilpiperazinil-ciclohexilindol para el tratamiento de la depresion.
US6972287B1 (en)	1999-06-10	2005-12-06	Pfizer Inc.	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
BR0011823A (pt) *	1999-06-22	2002-03-19	Neurosearch As	Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
US6610713B2 (en)	2000-05-23	2003-08-26	North Shore - Long Island Jewish Research Institute	Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
PE20020063A1 (es) *	2000-06-20	2002-01-30	Upjohn Co	Bis-arilsulfonas como ligandos del receptor de 5-ht
US20040122090A1 (en)	2001-12-07	2004-06-24	Lipton Stuart A.	Methods for treating neuropsychiatric disorders with nmda receptor antagonists
WO2002074293A2 (en)	2001-03-15	2002-09-26	Saegis Pharmaceuticals Inc	Methods for restoring cognitive function following systemic stress
US20030095958A1 (en) *	2001-04-27	2003-05-22	Bhisetti Govinda R.	Inhibitors of bace
BR0209558A (pt) *	2001-05-11	2004-04-20	Biovitrum Ab	Novos compostos de arilsulfonamida para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc
US6825198B2 (en) *	2001-06-21	2004-11-30	Pfizer Inc	5-HT receptor ligands and uses thereof
US6638981B2 (en)	2001-08-17	2003-10-28	Epicept Corporation	Topical compositions and methods for treating pain
KR20040048411A (ko) *	2001-09-14	2004-06-09	메틸진, 인크.	히스톤 데아세틸라아제의 억제제
AU2003220184A1 (en) *	2002-03-20	2003-10-08	Schering Aktiengesellschaft	Substituted piperazine antithrombotic pai-1 inhibitors
AU2003298514A1 (en)	2002-05-17	2004-05-04	Eisai Co., Ltd.	Methods and compositions using cholinesterase inhibitors
TW200403243A (en)	2002-07-18	2004-03-01	Wyeth Corp	1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
DK1534286T3 (da)	2002-07-29	2010-04-26	Rigel Pharmaceuticals Inc	Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
WO2004078732A1 (fr)	2003-01-28	2004-09-16	Aventis Pharma S.A.	Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation
US7153858B2 (en)	2003-01-31	2006-12-26	Epix Delaware, Inc.	Arylpiperazinyl compounds
AR043467A1 (es)	2003-03-05	2005-07-27	Osmotica Argentina S A	Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
GB0305929D0 (en) *	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
US7612078B2 (en)	2003-03-31	2009-11-03	Epix Delaware, Inc.	Piperidinylamino-thieno[2,3-D] pyrimidine compounds
ATE511511T1 (de)	2003-03-31	2011-06-15	Trovis Pharmaceuticals Llc	Neue piperidinylaminothienoä2,3-dü pyrimidinverbindungen
US20050222175A1 (en)	2004-03-31	2005-10-06	Dhanoa Dale S	New piperidinylamino-thieno[2,3-D] pyrimidine compounds
WO2005000217A2 (en)	2003-06-06	2005-01-06	Merck & Co., Inc.	Combination therapy for the treatment of dyslipidemia
AU2003261255A1 (en)	2003-07-24	2005-03-07	Cargill, Incorporated	A food composition contain lecithin
ES2222827B1 (es)	2003-07-30	2006-03-01	Laboratorios Del Dr. Esteve, S.A.	Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
GB0321710D0 (en) *	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
US20050143350A1 (en)	2003-11-19	2005-06-30	Seed John C.	Combination drug therapy to treat obesity
AU2005215775B2 (en)	2004-02-13	2011-02-03	Neuromolecular, Inc.	Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions
US7488736B2 (en)	2004-05-17	2009-02-10	Epix Delaware, Inc.	Thienopyridinone compounds and methods of treatment
GB0411791D0 (en) *	2004-05-26	2004-06-30	Cyclacel Ltd	Compounds
US7576211B2 (en)	2004-09-30	2009-08-18	Epix Delaware, Inc.	Synthesis of thienopyridinone compounds and related intermediates
US7598265B2 (en)	2004-09-30	2009-10-06	Epix Delaware, Inc.	Compositions and methods for treating CNS disorders
US7713954B2 (en)	2004-09-30	2010-05-11	Roche Palo Alto Llc	Compositions and methods for treating cognitive disorders
US7407966B2 (en)	2004-10-07	2008-08-05	Epix Delaware, Inc.	Thienopyridinone compounds and methods of treatment
US20060240043A1 (en)	2004-10-08	2006-10-26	Meyerson Laurence R	Methods and compositions for treating migraine pain
JP5132319B2 (ja) *	2004-12-21	2013-01-30	スミスクラインビーチャムコーポレーション	２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
BRPI0519424B8 (pt)	2004-12-28	2021-05-25	Athenex Inc	compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
EP1695971A1 (en) *	2004-12-30	2006-08-30	Laboratorios Del Dr. Esteve, S.A.	Substituted phenyl-piperazine compounds, their preparation and use in medicaments
EP1676842A1 (en) *	2004-12-30	2006-07-05	Laboratorios Del Dr. Esteve, S.A.	Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
BRPI0606110A2 (pt)	2005-01-25	2009-06-02	Epix Delaware Inc	compostos de arilamina substituìdos e seu uso como 5 - ht6 moduladores
EP1881756B1 (en)	2005-02-11	2016-08-10	Stephen Wills	Treating microvasculature diseases with acetyl cholinesterase inhibitors
US20060194723A1 (en)	2005-02-28	2006-08-31	Rabinoff Michael D	Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
EP2201963B1 (en)	2005-04-05	2016-01-27	Yale University	Glutamate modulating agents in the treatment of mental disorders
US20060270650A1 (en)	2005-05-26	2006-11-30	Macneil Tanya	Combination therapy for the treatment of obesity
US7919519B2 (en)	2005-11-23	2011-04-05	Epix Pharmaceuticals Inc.	S1P receptor modulating compounds and use thereof
AU2006317689B2 (en)	2005-11-23	2013-07-25	Epix Delaware, Inc.	S1P receptor modulating compounds and use thereof
WO2007109330A2 (en)	2006-03-21	2007-09-27	Epix Delaware, Inc.	S1p receptor modulating compounds

2006
- 2006-01-25 BR BRPI0606110-9A patent/BRPI0606110A2/pt not_active IP Right Cessation
- 2006-01-25 NZ NZ556761A patent/NZ556761A/en not_active IP Right Cessation
- 2006-01-25 US US11/340,079 patent/US7968538B2/en not_active Expired - Fee Related
- 2006-01-25 EP EP06719542A patent/EP1856075A1/en not_active Withdrawn
- 2006-01-25 AU AU2006209216A patent/AU2006209216A1/en not_active Abandoned
- 2006-01-25 JP JP2007552407A patent/JP5186219B2/ja not_active Expired - Fee Related
- 2006-01-25 RU RU2007132161/04A patent/RU2440996C2/ru not_active IP Right Cessation
- 2006-01-25 MX MX2007008279A patent/MX2007008279A/es active IP Right Grant
- 2006-01-25 WO PCT/US2006/002718 patent/WO2006081332A1/en not_active Ceased
- 2006-01-25 KR KR1020077019390A patent/KR20070097590A/ko not_active Ceased
- 2006-01-25 CA CA2595607A patent/CA2595607C/en not_active Expired - Fee Related
2007
- 2007-07-18 IL IL184705A patent/IL184705A0/en unknown
- 2007-08-07 MA MA30129A patent/MA29429B1/fr unknown
- 2007-08-24 NO NO20074324A patent/NO20074324L/no not_active Application Discontinuation
2011
- 2011-05-10 US US13/104,450 patent/US8604021B2/en not_active Expired - Fee Related
2012
- 2012-03-16 JP JP2012060984A patent/JP2012111784A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2008528517A (ja)	2008-07-31
EP1856075A1 (en)	2007-11-21
JP2012111784A (ja)	2012-06-14
US20120115850A1 (en)	2012-05-10
KR20070097590A (ko)	2007-10-04
US7968538B2 (en)	2011-06-28
AU2006209216A1 (en)	2006-08-03
US20060205737A1 (en)	2006-09-14
CA2595607C (en)	2014-07-15
WO2006081332A1 (en)	2006-08-03
BRPI0606110A2 (pt)	2009-06-02
NZ556761A (en)	2011-04-29
MA29429B1 (fr)	2008-05-02
IL184705A0 (en)	2007-12-03
CA2595607A1 (en)	2006-08-03
RU2007132161A (ru)	2009-03-10
US8604021B2 (en)	2013-12-10
MX2007008279A (es)	2008-02-15
JP5186219B2 (ja)	2013-04-17
RU2440996C2 (ru)	2012-01-27

Legal Events

Date	Code	Title	Description
2013-08-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20074324L (no)	2007-10-25	Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorer
AU2019219123B2 (en)	2022-12-08	Non-fused thiophene derivatives and their uses
CA2994688C (en)	2020-11-03	1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
ES2436103T3 (es)	2013-12-27	Derivados de isoxazol y uso de los mismos
AU2015230127B2 (en)	2017-04-20	Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
WO2005012221A1 (ja)	2005-02-10	ジフェニルエーテル化合物、その製造方法および用途
ES2963111T3 (es)	2024-03-25	Derivados de 4-(1,3,4-oxadiazol-2-il)piridina-2(1H)-ona como inhibidores de la histona desacetilasa 6 (HDAC6) para el tratamiento de infecciones E.G
CN102405209A (zh)	2012-04-04	二酰基乙二胺化合物
TW200808807A (en)	2008-02-16	Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
EP1778229A2 (en)	2007-05-02	Amido compounds and their use as pharmaceuticals
CA2572135A1 (en)	2006-01-05	Sulfonamide compound
KR20060010717A (ko)	2006-02-02	신규한 아릴피페라지닐 화합물
KR20100065195A (ko)	2010-06-15	바이아릴 설폰아미드 유도체
JP2021514963A (ja)	2021-06-17	ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体
JP4422335B2 (ja)	2010-02-24	グアニル酸シクラーゼ活性化剤としてのスルホニルアミノカルボン酸ｎ−アリールアミド
ES2782357T3 (es)	2020-09-14	Inhibidores de IRE 1 alfa
US20090163549A1 (en)	2009-06-25	Pharmaceutical Composition Comprising an Amide Derivative
AU2021337476B2 (en)	2024-08-08	Novel biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof
WO2005030706A1 (ja)	2005-04-07	アミド型カルボキサミド誘導体
KR20110045095A (ko)	2011-05-03	Ｖｅｇｆｒ-2 수용체 및 단백질 티로신 키나아제 억제제인 피리딘 유도체
TR201808812T4 (tr)	2018-07-23	Fenil derivesi.
US6727266B2 (en)	2004-04-27	Substituted tryptophan derivatives
US9365533B2 (en)	2016-06-14	Coumarin derivative
US8227492B2 (en)	2012-07-24	Sulfoxamine derivatives as factor Xa inhibitors
EA017306B1 (ru)	2012-11-30	Селективный агонист tr-бета 1